Mehdi Rashighi Firoozabadi
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 9 | 2018 | 120 | 2.810 |
Why?
|
| Dermatomyositis | 3 | 2026 | 9 | 1.370 |
Why?
|
| Melanocytes | 4 | 2018 | 77 | 1.160 |
Why?
|
| Autoimmunity | 3 | 2026 | 247 | 1.080 |
Why?
|
| Skin | 5 | 2026 | 422 | 0.990 |
Why?
|
| Telangiectasis | 1 | 2021 | 7 | 0.670 |
Why?
|
| Palate, Hard | 1 | 2020 | 4 | 0.640 |
Why?
|
| Erythema | 1 | 2020 | 13 | 0.640 |
Why?
|
| Exanthema | 1 | 2020 | 27 | 0.630 |
Why?
|
| Alopecia Areata | 2 | 2016 | 10 | 0.610 |
Why?
|
| Autoantibodies | 1 | 2020 | 184 | 0.590 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 380 | 0.530 |
Why?
|
| Immunologic Memory | 1 | 2018 | 283 | 0.490 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 169 | 0.480 |
Why?
|
| Transcription Factors | 2 | 2021 | 1554 | 0.470 |
Why?
|
| Chemokines | 1 | 2016 | 92 | 0.470 |
Why?
|
| Chemokine CXCL10 | 3 | 2017 | 56 | 0.470 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2018 | 675 | 0.460 |
Why?
|
| Immunotherapy | 1 | 2016 | 274 | 0.410 |
Why?
|
| Photosensitivity Disorders | 1 | 2026 | 5 | 0.240 |
Why?
|
| Keratinocytes | 1 | 2026 | 71 | 0.230 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2026 | 65 | 0.230 |
Why?
|
| Adaptive Immunity | 2 | 2017 | 104 | 0.230 |
Why?
|
| Chemokine CXCL9 | 2 | 2017 | 23 | 0.230 |
Why?
|
| Receptors, CXCR3 | 2 | 2017 | 35 | 0.230 |
Why?
|
| Myeloid Cells | 1 | 2026 | 98 | 0.230 |
Why?
|
| Skin Pigmentation | 2 | 2015 | 33 | 0.220 |
Why?
|
| Interferon Type I | 1 | 2026 | 196 | 0.210 |
Why?
|
| Fibroblasts | 1 | 2026 | 422 | 0.200 |
Why?
|
| Immunity, Innate | 3 | 2017 | 822 | 0.180 |
Why?
|
| Humans | 11 | 2026 | 65141 | 0.170 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 22 | 0.160 |
Why?
|
| Interferon-gamma | 3 | 2017 | 574 | 0.150 |
Why?
|
| Methotrexate | 1 | 2020 | 80 | 0.150 |
Why?
|
| Mice, Transgenic | 3 | 2018 | 1290 | 0.150 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 2293 | 0.140 |
Why?
|
| Mice | 5 | 2026 | 11114 | 0.140 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 991 | 0.130 |
Why?
|
| Self Tolerance | 1 | 2017 | 20 | 0.130 |
Why?
|
| Blister | 1 | 2017 | 15 | 0.130 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 71 | 0.130 |
Why?
|
| Phototherapy | 1 | 2017 | 33 | 0.130 |
Why?
|
| Flow Cytometry | 1 | 2018 | 662 | 0.130 |
Why?
|
| Hypopigmentation | 1 | 2016 | 15 | 0.120 |
Why?
|
| Bullying | 1 | 2016 | 16 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2016 | 61 | 0.120 |
Why?
|
| Regeneration | 1 | 2017 | 125 | 0.120 |
Why?
|
| Pyrazoles | 1 | 2015 | 88 | 0.110 |
Why?
|
| Hair | 1 | 2015 | 81 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 237 | 0.110 |
Why?
|
| Antioxidants | 1 | 2017 | 249 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2017 | 321 | 0.110 |
Why?
|
| Simvastatin | 1 | 2014 | 26 | 0.110 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 361 | 0.110 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 197 | 0.110 |
Why?
|
| Animals | 5 | 2026 | 21333 | 0.100 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 37 | 0.100 |
Why?
|
| High Mobility Group Proteins | 1 | 2013 | 27 | 0.100 |
Why?
|
| Interleukin-17 | 1 | 2013 | 99 | 0.090 |
Why?
|
| Intestines | 1 | 2013 | 178 | 0.090 |
Why?
|
| Signal Transduction | 3 | 2016 | 3149 | 0.080 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 5614 | 0.080 |
Why?
|
| Male | 4 | 2021 | 31055 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1008 | 0.070 |
Why?
|
| Cells, Cultured | 2 | 2026 | 2188 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2026 | 147 | 0.060 |
Why?
|
| Female | 3 | 2026 | 34030 | 0.050 |
Why?
|
| Aged | 1 | 2021 | 14963 | 0.050 |
Why?
|
| Inflammation | 1 | 2026 | 1187 | 0.040 |
Why?
|
| Chemokine CXCL11 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Suction | 1 | 2017 | 33 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 292 | 0.030 |
Why?
|
| Psoriasis | 1 | 2016 | 59 | 0.030 |
Why?
|
| Nitriles | 1 | 2015 | 82 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2015 | 145 | 0.030 |
Why?
|
| Pigmentation | 1 | 2014 | 25 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 35 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 371 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1141 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2013 | 3 | 0.020 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2013 | 10 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2013 | 12 | 0.020 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 9 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 16 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2013 | 44 | 0.020 |
Why?
|
| Interleukins | 1 | 2013 | 87 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 214 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 69 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 197 | 0.020 |
Why?
|
| Autoantigens | 1 | 2013 | 139 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2013 | 160 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 1480 | 0.020 |
Why?
|
| Cytokines | 1 | 2014 | 952 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2014 | 1036 | 0.020 |
Why?
|
| Adult | 2 | 2017 | 17358 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2013 | 2156 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2013 | 1386 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4812 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 6306 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 18273 | 0.010 |
Why?
|